Novartis licenses Alteogen’s hyaluronidase enzyme ALT-B4 in new drug delivery partnership
Novartis announced a licensing agreement with South Korean biotech Alteogen to use its hyaluronidase enzyme ALT-B4 for drug delivery applications.
The enzyme will be produced using Alteogen’s proprietary platform, allowing Novartis to incorporate it into its development pipeline.
The deal expands Novartis’s portfolio of delivery technologies and could accelerate the creation of subcutaneous formulations for its pipeline candidates.
In separate news, Cellares reported additional workforce reductions, continuing recent cost‑cutting measures.
The article also referenced other companies such as Novonesis, Aspen, Fortrea and Northway but provided no further details.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Novartis' drug delivery deal with Alteogen; More worker cuts at Cellares”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that